FDA touts progress on demographic information in Clinical Trials

Recent Progress on Demographic Information and Clinical Trials (FDA blog) At FDA, one of our foremost responsibilities is to evaluate and if medical products meets the appropriate standard, to approve or clear drugs, biological products and medical devices. We know that these products are safer and more effective for everyone when they are tested in clinical trials that include diverse populations. The design and analysis of clinical trials has evolved significantly over the last three decades.  FDA now has a variety of statutory, regulatory, and policy-related tools at its disposal that provi...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top